We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01850758
Previous Study | Return to List | Next Study

Regenexx™ SD Versus Exercise Therapy for ACL Tears

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01850758
Recruitment Status : Completed
First Posted : May 9, 2013
Last Update Posted : July 8, 2022
Information provided by (Responsible Party):
Regenexx, LLC

Brief Summary:

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months.

Secondary objectives include evaluation of MRI evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

Condition or disease Intervention/treatment Phase
Anterior Cruciate Ligament Tear Procedure: Regenexx SD Other: Exercise Therapy Not Applicable

Detailed Description:

Prospective, randomized, controlled to include 25 subjects treated with Regenexx SD and 25 subjects treated with exercise therapy alone with the exercise group crossing over to the injection group at 3 months.

Subjects will have a partial or complete, non-retracted ACL ligament tear as evidenced with MRI.

Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of exercise therapy and take part in follow-up visits for two years following treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection.

The primary endpoint analysis will be conducted once all subjects reach the 3 month endpoint. Subjects will continue to be followed through the 2 year endpoint with data analysis performed at the 1 year and 2 year time points.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears
Study Start Date : May 2013
Actual Primary Completion Date : May 22, 2020
Actual Study Completion Date : March 8, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Regenexx SD
Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
Procedure: Regenexx SD
stem cell treatment

Active Comparator: Exercise Therapy
Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
Other: Exercise Therapy
exercise therapy control

Primary Outcome Measures :
  1. IKDC Subjective Knee Evaluation Score Change from Baseline [ Time Frame: Change from Baseline to 3 months ]
    The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in IKDC scores.

Secondary Outcome Measures :
  1. Mean Pain Scales [ Time Frame: 3, 6, 12 and 24 months ]
    Difference between treatment groups in mean 0-10 pain scales at each follow-up timepoint

  2. Magnetic Resonance Evaluation of ligament repair [ Time Frame: 6 months ]
    Comparison of Magnetic Resonance Evaluation of ligament repair at 6 months

  3. Mean IKDC Subjective Knee Evaluation Scores [ Time Frame: 6, 12 and 24 months ]
    Difference between treatment groups in mean KDC Subjective Knee Evaluation Scores at 6, 12 and 24 months.

  4. Incidence of complications and adverse events [ Time Frame: 24 months ]
    Incidence and time to resolution of post-operative complications and adverse events between treatment groups.

  5. Incidence of re-injection and surgical revision [ Time Frame: 24 months ]
    Incidence of and time to re-injection and surgical revision between treatment groups.

  6. Use of pain medications [ Time Frame: 3, 6, 12 and 24 months ]
    Difference between treatment groups in use of pain medications at each follow-up timepoint

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pain, swelling, or functional disability in the affected knee with activity, having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months or unable to return to normal day to day activities by 6 weeks
  • Physical examination consistent with lax ACL ligament (Anterior Drawer Test)
  • Abnormal Telos Arthrometer measurement
  • Positive diagnostic MR imaging of the affected knee with at least 1/3 of the ACL ligament at any area along its length having high signal on MRI PDFS/Fat Sat images.
  • Full range of motion of the affected knee (other than restriction clearly due to effusion)
  • Normal range of motion of the non-treated knee
  • Is independent, ambulatory, and can comply with all post-operative evaluations and visits

Exclusion Criteria:

  • A massive ACL tear or one that includes more than 2/3'rds of the ligament that's retracted.
  • Previous surgery to the affected ACL (i.e. previous ACL replacement with an autograft or allograft)
  • Prior ACL prolotherapy, PRP, corticosteroid injection or other injection therapy within the past three months,
  • Concomitant meniscus tear or cartilage injury that occurred at the same time as the as the ACL tear and which is considered a pain generator by the treating physician at the time intake into the study (i.e. a meniscus tear or cartilage lesion associated with an active BML).
  • Concomitant PCL or LCL tears
  • Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
  • Quinolone or Statin induced myopathy/ tendinopathy
  • Kellgren-Lawrence grade 2 or greater knee osteoarthritis
  • Significant knee extension lag compared to the opposite knee
  • Symptomatic lumbar spine pathology (e.g. radicular pain)
  • Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh
  • Contraindications for MRI
  • Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site
  • Condition represents a worker's compensation case
  • Currently involved in a health-related litigation procedure
  • Is pregnant
  • Bleeding disorders
  • Currently taking anticoagulant or immunosuppressive medication
  • Allergy or intolerance to study medication
  • Use of chronic opioid,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01850758

Layout table for location information
United States, Colorado
Centeno-Schultz Clinic
Broomfield, Colorado, United States, 80021
Sponsors and Collaborators
Regenexx, LLC
Layout table for investigator information
Principal Investigator: Christopher Centeno, MD Centeno-Schultz Clinic
Layout table for additonal information
Responsible Party: Regenexx, LLC
ClinicalTrials.gov Identifier: NCT01850758    
Other Study ID Numbers: RSI2013-RCT01
First Posted: May 9, 2013    Key Record Dates
Last Update Posted: July 8, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Regenexx, LLC:
Anterior Cruciate Ligament
ACL Tear
Anterior Cruciate Ligament Tear
Partial ACL Tear
Additional relevant MeSH terms:
Layout table for MeSH terms
Anterior Cruciate Ligament Injuries
Wounds and Injuries
Knee Injuries
Leg Injuries